Evidence map›Paper›PMID 29117787›Full record

ArticleStem cells and development2018

Reprogramming of Adult Peripheral Blood Cells into Human Induced Pluripotent Stem Cells as a Safe and Accessible Source of Endothelial Cells.

Pavel Simara, Lenka Tesarova, Daniela Rehakova, Simon Farkas, Barbara Salingova, Katerina Kutalkova, Eva Vavreckova, Pavel Matula, Petr Matula, Lenka Veverkova and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Stem cells and development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. The Effect of Uncoated SPIONs on hiPSC-Differentiated Endothelial Cells.International journal of molecular sciences · 2019
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Pavel Simara1 Centre for Biomedical Image Analysis, Faculty of Informatics, Masaryk University , Brno, Czech Republic .
Lenka Tesarova1 Centre for Biomedical Image Analysis, Faculty of Informatics, Masaryk University , Brno, Czech Republic .
Daniela Rehakova1 Centre for Biomedical Image Analysis, Faculty of Informatics, Masaryk University , Brno, Czech Republic .
Simon Farkas1 Centre for Biomedical Image Analysis, Faculty of Informatics, Masaryk University , Brno, Czech Republic .
Barbara Salingova1 Centre for Biomedical Image Analysis, Faculty of Informatics, Masaryk University , Brno, Czech Republic .
Katerina Kutalkova1 Centre for Biomedical Image Analysis, Faculty of Informatics, Masaryk University , Brno, Czech Republic .
Eva Vavreckova1 Centre for Biomedical Image Analysis, Faculty of Informatics, Masaryk University , Brno, Czech Republic .
Pavel Matula1 Centre for Biomedical Image Analysis, Faculty of Informatics, Masaryk University , Brno, Czech Republic .
Petr Matula1 Centre for Biomedical Image Analysis, Faculty of Informatics, Masaryk University , Brno, Czech Republic .
Lenka Veverkova3 I. Surgery Department, St. Anne's University Hospital Brno , Brno, Czech Republic .
Irena Koutna1 Centre for Biomedical Image Analysis, Faculty of Informatics, Masaryk University , Brno, Czech Republic .
Masaryk University · CZSt. Anne's University Hospital Brno · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New approaches in regenerative medicine and vasculogenesis have generated a demand for sufficient numbers of human endothelial cells (ECs). ECs and their progenitors reside on the interior surface of blood and lymphatic vessels or circulate in peripheral blood; however, their numbers are limited, and they are difficult to expand after isolation. Recent advances in human induced pluripotent stem cell (hiPSC) research have opened possible avenues to generate unlimited numbers of ECs from easily accessible cell sources, such as the peripheral blood. In this study, we reprogrammed peripheral blood mononuclear cells, human umbilical vein endothelial cells (HUVECs), and human saphenous vein endothelial cells (HSVECs) into hiPSCs and differentiated them into ECs. The phenotype profiles, functionality, and genome stability of all hiPSC-derived ECs were assessed and compared with HUVECs and HSVECs. hiPSC-derived ECs resembled their natural EC counterparts, as shown by the expression of the endothelial surface markers CD31 and CD144 and the results of the functional analysis. Higher expression of endothelial progenitor markers CD34 and kinase insert domain receptor (KDR) was measured in hiPSC-derived ECs. An analysis of phosphorylated histone H2AX (γH2AX) foci revealed that an increased number of DNA double-strand breaks upon reprogramming into pluripotent cells. However, differentiation into ECs restored a normal number of γH2AX foci. Our hiPSCs retained a normal karyotype, with the exception of the HSVEC-derived hiPSC line, which displayed mosaicism due to a gain of chromosome 1. Peripheral blood from adult donors is a suitable source for the unlimited production of patient-specific ECs through the hiPSC interstage. hiPSC-derived ECs are fully functional and comparable to natural ECs. The protocol is eligible for clinical applications in regenerative medicine, if the genomic stability of the pluripotent cell stage is closely monitored.

Indexed as

BiomarkersCell DifferentiationCells, CulturedEndothelial CellsFibroblastsHumansHuman Umbilical Vein Endothelial CellsInduced Pluripotent Stem CellsLeukocytes, MononuclearNeovascularization, PhysiologicRegenerative MedicineBiomarkersendothelial differentiationinduced pluripotent stem cellsperipheral blood mononuclear cells

Identifiers

PMID29117787
PMCPMC5756468
OpenAlexW2767743827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.